EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $25.71 Average PT from Analysts

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have earned a consensus rating of “Buy” from the nine brokerages that are presently covering the firm, MarketBeat reports. Nine equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have covered the stock in the last year is $25.71.

Several equities research analysts recently issued reports on EYPT shares. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, December 5th. Robert W. Baird dropped their price target on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. Scotiabank initiated coverage on shares of EyePoint Pharmaceuticals in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 price objective on the stock. StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a research note on Saturday, September 21st. Finally, Chardan Capital boosted their price target on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, November 8th.

EyePoint Pharmaceuticals Price Performance

NASDAQ:EYPT opened at $7.10 on Wednesday. The company has a market cap of $484.58 million, a P/E ratio of -3.55 and a beta of 1.45. EyePoint Pharmaceuticals has a 1 year low of $6.90 and a 1 year high of $30.99. The stock’s fifty day moving average price is $9.74 and its two-hundred day moving average price is $9.12.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. boosted its holdings in shares of EyePoint Pharmaceuticals by 68.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock valued at $82,000 after acquiring an additional 4,172 shares during the last quarter. Greenwich Wealth Management LLC purchased a new position in EyePoint Pharmaceuticals during the second quarter valued at $94,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in EyePoint Pharmaceuticals by 271.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock valued at $95,000 after purchasing an additional 7,953 shares during the period. Cyndeo Wealth Partners LLC bought a new position in shares of EyePoint Pharmaceuticals in the third quarter worth about $100,000. Finally, Arizona State Retirement System lifted its position in shares of EyePoint Pharmaceuticals by 9.7% during the 2nd quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $115,000 after buying an additional 1,171 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.